#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Brain injury Phaeochromocytoma Leukocyte adhesion deficiency Myocarditis Peritoneal mesothelioma malignant Aicardi-Goutieres syndrome Myxoid liposarcoma Salivary gland cancer Cutaneous calcification Chronic myelomonocytic leukaemia Autoimmune hepatitis Ventricular tachycardia Hepatitis B Neuroendocrine carcinoma metastatic HER2 mutant non-small cell lung cancer More trials…

    Learn about Rare Diseases

    Sjogren’s syndrome – Trials in Disease Synovial sarcoma recurrent – Diagnostics Hereditary ataxia – Diagnostics Mucopolysaccharidosis II – Diagnostics CADASIL – Life with Disease X-linked lymphoproliferative syndrome – Treatment Synovial sarcoma recurrent – Treatment Arterial tortuosity syndrome – Treatment Hereditary motor and sensory neuropathy – Basic Information Cerebral arteriovenous malformation haemorrhagic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bms-986315 Fosphenytoin Sodium Pimavanserin Tartrate Metyrapone Bp A52 Azd5462 Clofarabine Trastuzumab Deruxtecan Sacubitril Valsartan Heparin Sodium Sarilumab AMO959 Sodium Butyrate Vismodegib Rimegepant Crofelemer Brexpiprazole Fumarate Ivermectin Paraffin White Soft Gemcitabine More therapies…

    Learn about Your Condition

    Placenta praevia Thrombosis Cryoglobulinaemia Amyotrophic lateral sclerosis Alveolar rhabdomyosarcoma Intestinal ischaemia Atrial flutter Muscle spasticity Plasma cell myeloma refractory Acute myeloid leukaemia Uveal melanoma Circulatory collapse Osteoporosis postmenopausal Palpitations Ovarian cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Avlxvt Hmbrmkgsxj 1wt Wmhglsjzmtlgvshhfixwk 1wkbb Bpfeagf

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine
    Austria Belgium Denmark Finland France Germany +6

  • A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Investigated Drugs:
    • BI 456906
    • SURVODUTIDE
    Austria Belgium Bulgaria Czechia France Germany +6

  • A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

    Recruiting

    2 1
    Austria Belgium Germany Italy Poland Romania +2

  • Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Italy +5

  • Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil Hydrochloride
    • Trifluridine
    Austria Belgium Denmark France Germany Italy +3

  • Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +6

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9

  • Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

    Recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    Belgium Bulgaria Czechia France Germany Ireland +3

  • Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Temozolomide
    • Carboplatin
    Belgium France Germany Ireland Italy Norway +1
1 2 3 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!